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Abstract
Background: Despite lack of outward signs, most individuals after non-disabling stroke (NDS) and transient
ischemic attack (TIA) have significant cardiovascular and cerebrovascular disease and are at high risk of a major
stroke, hospitalization for other vascular events, or death. Most have multiple modifiable risk factors (e.g.,
hypertension, physical inactivity, hyperlipidaemia, diabetes, tobacco consumption, psychological stress). In
addition, accelerated rates of depression, cognitive decline, and poor quality of sleep have been reported
following TIA, which correlate with poor functional outcomes and reduced quality of life. Thus, NSD and TIA are
important warning signs that should not be overlooked. The challenge is not unlike that facing other ‘silent’
conditions - to identify a model of care that is effective in changing people’s current behaviors in order to avert
further morbidity.
Methods/Design: A single blind, randomized controlled trial will be conducted at two sites to compare the
effectiveness of a program of rehabilitative exercise and education versus usual care in modifying vascular risk
factors in adults after NDS/TIA. 250 adults within 90 days of being diagnosed with NDS/TIA will be randomly
allocated to a 12-week program of exercise and education (PREVENT) or to an outpatient clinic assessment and
discussion of secondary prevention recommendations with return clinic visits as indicated (USUAL CARE). Primary
outcome measures will include blood pressure, waist circumference, 12-hour fasting lipid profile, and 12-hour
fasting glucose/hemoglobin A1c. Secondary measures will include exercise capacity, walking endurance, physical
activity, cognitive function, depression, goal attainment and health-related quality of life. Outcome assessment will
be conducted at baseline, post-intervention, and 6- and 12-month follow-ups. Direct health care costs incurred
over one year by PREVENT versus USUAL CARE participants will also be compared. Ethical approval for the trial has
been obtained from the relevant Human Research Ethics Boards.
Discussion: Whether timely delivery of an adapted cardiac rehabilitation model is effective in attaining and
maintaining vascular risk reduction targets in adults after NDS/TIA is not yet known. We anticipate that the findings
of this trial will make a meaningful contribution to the knowledge base regarding secondary stroke prevention.
Trial registration: This trial is registered with the Clinical Trials.gov Registry (NCT00885456).
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“Little stroke, big trouble”,t h et h e m eo fW o r l dS t r o k e
Day 2008, speaks to the importance of heeding non-
disabling stroke (NDS) and transient ischemic attack
(TIA) as critical warning signs of further, more debilitat-
ing vascular events or death [1]. (Since the etiology and
prognosis of NDS and TIA are essentially the same [2],
h e r e a f t e rt h e yw i l lb er e f e r r e dt oa sas i n g l ee n t i t y-
NDS/TIA.) Until recently, the prognosis of NDS/TIA
was deemed relatively benign because NDS/TIA appears
to leave minimal impairment and no overt long-term
effects [3]. However, many survivors of NDS/TIA have
significant cardiovascular and cerebrovascular disease
and a high probability of secondary stroke or death [4] -
from 10% in the low-risk group, to 19% in moderate-
risk group and 31% in high-risk group [5]. Thus,
secondary prevention strategies are needed to avoid
disabling stroke, the fourth leading cause of disease bur-
den and the second leading cause of death among adults
worldwide [6]. Moreover, recurrent strokes contribute
disproportionately to the overall personal and economic
burden associated with stroke [7] because of higher
rates of institutionalisation and fatality than primary
strokes [8].
Individuals presenting with NDS/TIA typically have
significant atherosclerotic lesions throughout their vas-
cular system and often manifest co-morbid cardiovascu-
lar disease (CVD) [9,10]. Not surprisingly, cardiac
disease is the leading cause of death in stroke survivors
[11,12]. It follows that CVD and stroke share common
risk factors. Among the modifiable factors are hyperten-
sion, diabetes, dyslipidemia, physical inactivity, obesity,
excessive alcohol consumption, and cigarette smoking
[13]. Systolic blood pressure (SBP) is the most robust
independent predictor of secondary vascular events such
as myocardial infarction or recurrent stroke [14]. Dia-
betes is a strong independent predictor of stroke during
t h ef i r s ty e a rp o s t - T I A ,w i t hr a t eo fs t r o k er e c u r r e n c e
being substantially higher in the diabetic stroke popula-
tion [15]. Although dyslipidemia is less well established
as a risk factor for stroke than for cardiac disease [16],
recent guidelines for patients post-TIA include the
administration of statin therapy with intensive lipid-low-
ering effects [17].
Both physical inactivity [18] and abdominal obesity
[19,20] are independent risk factors for primary stroke.
We documented that mean exercise capacity (peak oxy-
gen consumption, VO2peak) at one-month post-stroke
was only 60% of normative values, increasing to 71% at
six months post-stroke [21]. Cigarette smoking has a
causal relationship to atheroscelerosis, which explains
why smoking is a major independent risk factor for
stroke [22]. Heavy alcohol use (> 5 drinks/day) is a
factor in stroke recurrence [23]. Metabolic syndrome, or
clustering of vascular risk factors, is defined by the
International Diabetes Federation as central obesity plus
any two of the following: hypertension, hypertriglycere-
mia, low high-density lipoprotein-cholesterol (HDL-C),
and insulin resistance [24]. This syndrome is critical in
the development of recurrent ischemic stroke [25] and
is also associated with silent brain infarction indepen-
dent of other risk factors [26]. Control of the risk factors
associated with metabolic syndrome is inadequate for
people post-TIA or stroke [27] In a cohort of stroke
survivors, 67% were overweight or obese, 80% had pre-
hypertension or hypertension, 34% had low HDL and
45% had impaired fasting glucose [28]. Among patients
post-stroke entering exercise studies, 99% of participants
had at least one uncontrolled risk factor and 91% had
two or more inadequately treated risk factors [28], fig-
ures comparable to what we reported in participants
beginning stroke rehabilitation [29]. The problem is
compounded by an acute lack of awareness and knowl-
edge of cardiovascular risk factors among the NDS/TIA
population [30]. Collectively, these findings suggest that
there is considerable room for improvement in vascular
risk factor management following NDS/TIA.
For people with CVD or diabetes, cardiac rehabilita-
tion programs, consisting of exercise, education and life-
style change counselling, improve all of the modifiable
risk factors discussed above. Two large trials reported
favourable effects of multi-modal cardiac rehabilitation
on hypertension [31,32]. Cochrane reviews concluded
that exercise alone [33], or the combination of exercise
and dietary advice [34], also improve glycemic control
(decrease in hemoglobin A1c) in people with type 2 dia-
betes. Benefits of group-based exercise sessions people
with type 2 diabetes include reductions in SBP, hemo-
globin A1c, fasting blood glucose levels, body weight
and need for diabetes medication, as well as enhanced
diabetes knowledge [35]. A ~50% reduction in risk of
vascular events over 7.8 year period was reported fol-
lowing an intensive program of exercise, dietary modifi-
cation and pharmacotherapy for people with type 2
diabetes [36]. Sustained moderate weight loss, achieved
through lifestyle interventions (diet and exercise), is
effective for the prevention and treatment of hyperten-
sion, diabetes and dyslipidemia [37,38]. Dietary advice
alone has been shown to improve lipid profiles [34]. A
systematic review found that comprehensive cardiac
rehabilitation, but not exercise alone, induced reductions
in total cholesterol, LDL-C and triglycerides, with no
effect on HDL-C [33]. Reviews of multi-modal cardiac
rehabilitation programs [33] and distribution of self-help
education materials[39] have revealed little effect on
smoking cessation.
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not only reduces mortality in cardiac populations
[32,40,41], but benefits mood [42], diminishes anxiety
and depression [43], improves cognition [44,45] and
decreases risk of dementia in vascular disease [46,47].
These additional benefits are relevant because people
with TIA/NDS can have subtle but persistent neuropsy-
chological deficits [48] similar to those accompanying
hypertension [49]. As well, reducing depressive sympto-
matology - a condition found in up to 70% people
post-TIA [50] - has been linked to decreased risk of
recurrent cerebrovascular events [51].
There is good reason to suggest that risk factor man-
agement for NDS/TIA should be aligned with that of
cardiovascular conditions, given that secondary risk fac-
tors, risk of recurrence, and the potential benefits of
treatment are similar [2]. Preliminary support for a
multi-faceted approach to secondary stroke prevention
comes from a modeling study in which the authors con-
cluded, ″At least four-fifths of recurrent vascular events
in patients with cerebrovascular disease might be pre-
vented by application of a comprehensive, multi-factorial
approach″ [52]. A non-randomized study of a 3-month
exercise program for patients within six months of
NDS/TIA demonstrated improvements in walking
endurance and exercise capacity [53]. Another non-
randomized study of an 8-week educational program for
people post-NDS/TIA demonstrated improved knowl-
edge regarding stroke warning signs, medication adher-
ence, blood pressure monitoring and reduction in salt
intake [54]. A recent pilot randomized trial of a 10-week
cardiac rehabilitation program for patients post-stroke
demonstrated greater improvement in cardiac risk
scores in the experimental group than the usual care
group [55]. However, high-level evidence of risk factor
reduction through non-pharmacological approaches is
lacking [56]. For the most part, secondary stroke pre-
vention trials have been short-term, focusing on phar-
macological interventions (for example [57,58]) and
endarterectomy for patient with surgical grade carotid
stenosis [59].
Little provision is made in current health services for
modification of lifestyle factors such as cardiovascular
fitness, weight optimization and healthy eating for long-
term secondary prevention in patients with NDS/TIA.
This situation is at odds with recommendations sup-
porting a combination of comprehensive lifestyle inter-
ventions and pharmacological therapy to prevent
recurrent stroke and acute cardiac events in stroke sur-
vivors [60,61]. Indeed, Myint and colleagues [62] postu-
lated that behavioral modifications may be as important
as anti-hypertensive and cholesterol lowering agents in
secondary prevention of stroke.
A major thrust in public health over the next decade
will be to focus attention on identification and manage-
ment of vascular risk factors. Although primary preven-
tion is the ultimate goal, resources will need to be
allocated to those who are at high risk and most likely
to gain the greatest benefit. One such group is people
who have experienced a NDS/TIA. The main objective
of the PREVENT trial is to determine whether the
timely delivery of a comprehensive program of second-
ary stroke prevention services and coordinated care can
improve long-term vascular risk reduction for patients
after NDS or TIA. The primary aim is to compare the
effectiveness of a program of rehabilitative exercise and
education (PREVENT) versus usual care (USUAL
CARE) in reducing vascular risk factors in people who
have had a NDS or TIA. Secondary aims are to compare
between PREVENT and USUAL CARE groups (i) exer-
cise capacity, walking endurance, daily physical activity,
number of cigarettes smoked daily, medication adher-
ence; (ii) fatigue, cognitive function, depression, health-
related goal attainment and health-related quality of life;
(iii) direct health costs incurred over a 1-year period;
(iv) reduction in secondary vascular events, within the
limitations in sample size and trial duration. We antici-
pate that, in comparison to USUAL CARE, timely deliv-
ery of PREVENT will produce clinically important and
sustainable improvements in the outcome variables.
Methods/design
All procedures involved in this trial with human partici-
pants will be conducted in compliance with institutional
ethical standards and the Helsinki Declaration. Ethical
approval to conduct the trial has been granted by the
Capital District Research Ethics Board (protocol CDHA-
RS/2009-371) and the Annapolis Valley District
Research Ethics Board (protocol #2009-005).
Study Design
This is a two parallel group, four-site, single-blinded,
randomized trial with group assignment stratified using
the Stroke Prognosis Instrument II (SPI-II) [5]. Figure 1
illustrates the sequencing of the study protocol.
Setting
Four community-based cardiac rehabilitation programs,
three located in one urban/suburban environment (Hali-
fax, Nova Scotia, Canada) and one in a more rural set-
ting (Kentville, Nova Scotia, Canada) have been selected
at intervention sites based on recruitment potential,
adherence to the national guidelines for hyperacute and
acute management of NDS and TIA [60], and availabil-
ity of existing programs that could be adapted to meet
the protocol for this trial.
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Inclusion Criteria
Participants will include males and females, over 17
years of age, who are within 90 days of diagnosis of first
probable or definite TIA (symptom resolution in less
than 24 hours) or ischemic or hemorrhagic NDS
(National Institutes of Health Stroke Scale less than 6)
[63] for which medical attention was sought.
Exclusion Criteria
Potential participants will be excluded if they present
with contraindications to exercise testing and training,
in accordance with American College of Sports Medi-
cine Guidelines (ACSM) [64] and/or are participating in
another study that could potentially confound the out-
comes of this trial.
Participant recruitment
Recruitment pamphlets approved by the Research Ethics
Board and checklists outlining the inclusion/exclusion
criteria will be distributed in emergency rooms, physi-
cians’ offices, stroke units, and outpatient stroke clinics.
The neurologists or internists directing acute stroke ser-
vices and emergency room physicians in the trial sites
will be trained to identify patients who meet the selec-
tion criteria and will notify the PREVENT Trial site
coordinator of potential research subjects. The site coor-
dinators will also communicate directly with the recruit-
ment locations twice weekly for potential participants
and will provide ongoing education, recruitment flyers,
and reminders about the trial. The site coordinators will
also review each candidate’s health record for inclusion/
exclusion criteria and record basic demographic and
medical information.
Eligible patients will be approached by the site coordi-
nator, who will briefly explain the purpose of the study
and ask if they have an interest in participating. If a
potential participant expresses interest, the study will be
explained in detail, all questions will be addressed and
the participant will be asked to sign the consent form
approved by the Research Ethics Board of that site. The
family physicians of the participants will be informed of
intent to participate. The Environmental Supports for
Physical Activity Questionnaire [65] will also be admi-
nistered. Those patients who do not wish to participate
will be asked to complete a brief questionnaire about
their daily physical activity, to assess the representative-
ness of the final study sample.
Sample Size
Systolic blood pressure, the most robust predictor of
secondary vascular events [14], was selected as the out-
come variable for sample size calculation. Using esti-
mates obtained from our pilot study, a sample size of
119 in each group will have 80% power to detect a dif-
ference in means of 4.9 mmHg, assuming that the
common standard deviation is 13.4 using a two group
t-test with a 0.05 two-sided significance level. We have
allowed for an overall attrition rate of 5% [55], thus
i n c r e a s i n gt h es a m p l es i z et o1 2 5p e rg r o u p( 2 5 0i n
total). The trial will not be sufficiently powered to
determine the effectiveness of the PREVENT interven-
tion in reducing recurrent TIA, stroke or cardiac
events. Thus, it will be exploratory in this regard and
will help inform the design of a future, more extensive
trial.
Randomization Procedures
Participants will be randomized to one of two interven-
tions: USUAL CARE or PREVENT. To ensure compar-
able groups in terms of neurological status, group
assignment will be stratified using the SPI-II, which
assesses long-term risk of stroke post-TIA or NDS using
a 15-point scale [5]. Two strata will be used: 1. SPI-II
L e v e l1( 0 - 3p o i n t s ;l o w - r i s k ) ,2 .S P I - I IL e v e l2( 4 - 7
points; moderate-risk), and Level 3 (8-15 points; high-
risk). An individual not associated with the study will
use a computerized random number generator to ran-
domly assign subjects to group. Allocation concealment
will be ensured by using opaque, a sealed envelope con-
taining group assignment, which will be revealed, in the
presence of the participant, after completion of the base-
line assessment. The participants (who are necessarily
unblinded) will be requested to avoid informing blinded
evaluators of their group assignment.
 
 
 
 
 
 
 
 
 
 
  
Recruitment of potential 
participants 
Randomization  
Stratified by recurrent stroke risk 
(n = 250) 
Baseline assessment 
Informed consent  
Screening for eligibility  
PREVENT 
12-week program 
2 75-minute exercise sessions/week 
1 90-minute education session/week 
Post-intervention assessment  
Follow-up assessment 
at 6 months 
Telephone follow-up 
at 4 and 5 months 
Telephone follow-up 
at 7-11 months 
Follow-up assessment 
at 12 months 
USUAL CARE 
3-4 clinic visits in 12 weeks 
(depending on patient's needs) 
Post-intervention assessment  
Follow-up assessment 
at 6 months 
Follow-up assessment 
at 12 months 
Figure 1 Flow chart outlining the study protocol.
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Given the long duration and multi-modal nature of the
interventions, a range of outcome measures will be used
to ensure evaluation of relevant variables that span the
domains of the International Classification of Function-
ing [66]. The variables and measurement tools that will
be employed are summarized in Table 1. These measures
were selected based on the primary and secondary aims
of the trial, clinical relevance, psychometric qualities, and
feasibility (availability, cost and administration time).
Evaluations will be conducted over a 2-day assessment
period at baseline, post-intervention, six months, and 12
months by trained assessors blinded to knowledge of
study hypotheses and group assignment. At each assess-
ment the assessors will be asked to record their ‘guess’ as
to the group assignment of each participant.
Interventions
USUAL CARE Intervention
Following completion of the acute management of TIA
and NDS, USUAL CARE participants will be referred to
the site’s outpatient Neurovascular Clinic, staffed by neu-
rologists/internists and nurses, for a neurological and
health assessment, counselling regarding stroke/TIA and
diagnostic test results, and assessment, modification and
education of secondary prevention factors (i.e., dietary
intake, lipid profile, adherence to medication regime,
physical activity, smoking, alcohol intake, elf-referral to
weight loss and smoking cessation programs) [78].
Required therapeutic interventions will be initiated or
adjusted (e.g., medications, diagnostic/laboratory tests)
and referrals will be sent to appropriate team members
or clinics (e.g. social worker, physiotherapist, occupa-
tional therapist, dietician, speech language pathologist,
diabetes clinic, hypertension clinic, anticoagulation clinic,
smoking cessation program). Follow-up care will be pro-
vided by return clinic visits, with an average of three vis-
its in total. Those patients who no longer require follow-
up will be referred back to their primary care physician.
PREVENT intervention
After completing the acute management of TIA and
NDS, PREVENT participants will participate in a multi-
Table 1 Outcome variables, measurement tools and assessment schedule
Variable Measurement tool Baseline Post-
intervention
6-month
follow-
up
12-month follow-
up
Primary measures
Blood pressure Sphygmomanometer [67] √√√ √
Waist girth Tape measure [68] √√√ √
Lipid profile* Biochemical analysis √√√ √
Fasting serum glucose Biochemical analysis √√√ √
Haemoglobin A1c Biochemical analysis √√√ √
Secondary measures
Aerobic fitness Peak VO2 using maximal treadmill stress test
(ramp protocol)
√√ √
Lower extremity function Short Physical Performance Test [69] √√√ √
Walking endurance Six-Minute Walk Test [70] √√√ √
Physical activity Step Watch™accelerometers √√ √
International Physical Activity Questionnaire [71] √√√ √
Fatigue levels Fatigue Assessment Scale [72] √√√ √
Cognition Montreal Cognitive Assessment [73] √√
Mental health Hospital Anxiety and Depression Scale [74] √√√ √
Quality of sleep Pittsburg Sleep Quality Index [75] √√√ √
Tobacco use Self-report, using a health passport √√√ √
Health care utilization Self-report, using a health passport √√√ √
Medication adherence Self-report, using a health passport √√√ √
Health-related quality
of life
Medical Outcomes Study Short-form 36-item
Questionnaire [76]
√√ √
Health-related goals Goal Attainment Scaling [77] √√√ √
Secondary vascular
events**
Health record abstraction √√√ √
*Includes total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides
**Includes second stroke, second TIA, acute coronary syndrome (i.e., unstable angina and myocardial infarction), heart failure, and vascular death
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tion. Because this intervention is behavior-focused (e.g.,
encouraging daily physical activity, health eating, smok-
ing cessation, medication use adherence), several strate-
gies known to facilitate and sustain behavioral change
have been incorporated into the design [79,80]:
(i) Each participant will meet with the PREVENT phy-
sicians and program providers to identify personal
goals/barriers/possible solutions related to risk factor
targets and lifestyle modifications, based on the baseline
assessment and the participant’s needs and values.
(ii) Each participant will be provided with a user-
friendly health passport in which the participant and
PREVENT staff will maintain documentation regarding
health-related appointments, assessment results, medica-
tions, BP, cigarettes smoked, lipid profile, blood glucose,
body weight, waist circumference, daily physical activity,
dietary intake, as well as goal attainment related to
these domains. All information in the passport will be
written in ‘plain language’ (i.e., Grade 8 reading level).
(iii) Use of positive reinforcement (encouragement,
positive feedback).
(iv) Use of adult learning strategies (interactive educa-
tional sessions, participant involvement in content
selection).
(v) After completion of the formal program, telephone
follow-up will be implemented (see below). In addition,
individual therapeutic interventions will be initiated or
adjusted, as described above for usual care.
Group exercise component 75-minute group exercise
sessions, lead by a physiotherapist or kinesiologist, will
be held twice weekly for 12 weeks. The sessions will
involve (i) 5-10 minutes of warm-up exercises, (ii) 15
minutes of progressive resistance training of major
extremity muscles, (iii) 30 minutes of aerobic training
consisting of three 10-minute stations of treadmill
walking, stationary cycling and stepping at an initial
intensity of 40-70% of heart rate reserve, as determined
by stress test results; (iv) 5-10 minutes of cool-down
exercise; (v) progressive resistive strengthening of
major upper and lower extremity muscle groups. Heart
rate will be continuously monitored, and BP and blood
sugars will be measured before and after exercise, as
indicated. Both strengthening and aerobic training will
be prescribed and progressed according to ACSM
guidelines [64].
Home exercise component Group exercise sessions will
be supplemented by 30 minutes of home cardiovascular
exercise, 3-4 days/week at a rating of perceived exertion
(RPE) of 3-5 on the Borg 0-10 scale [81,82].
Education component One 1.5-hour group session
will be conducted weekly by a multi-disciplinary team of
health professionals. The schedule for the educational
sessions and topics of discussion are outlined in Table
2. Family members/caregivers of participants will be
encouraged to attend. Powerpoint slides will be used to
ensure consistency of information across sites. Partici-
pants will also have access to scheduled grocery shop-
ping tours and cooking demonstrations to further
support program objectives.
Intervention audits All professionals involved in deli-
vering PREVENT will receive standardized training to
ensure consistency of program delivery across sites. To
appraise the actual level of consistency, audits will be
conducted at random intervals by the trial coordinator.
Any deviations from the protocol will be rectified by the
site PREVENT team.
Post-program follow-up After the 12-week program,
PREVENT participants will be provided with a written
maintenance program based on their long-term goals.
Participants will be requested to maintain their health
passport and will be phoned monthly by the site coordi-
nator until the 12-month follow-up as a means of moni-
toring of use of health passport, health status, health
care utilization and adherence to the maintenance
program.
Table 2 Schedule and discussion topics for educational sessions
Week 1 Heart healthy eating: The basics
Week 2 Setting of health-related goals
Week 3 Exercise: The basics
Week 4 Cardiovascular risk factors and BP self-monitoring
Week 5 Nutrition: Building on the basics (including a 3-day food record analysis by the dietician)
Week 6 Exercise: Building on the basics
Week 7 Cardiovascular medications
Week 8 Healthy weight
Week 9 Smoking cessation
Week 10 Stress & coping
Week 11 Fine-tuning healthy eating
Week 12 Wrap-up
MacKay-Lyons et al. BMC Neurology 2010, 10:122
http://www.biomedcentral.com/1471-2377/10/122
Page 6 of 9Data management and analysis
Data collected at each site will be recorded on standar-
dized forms and entered into a secure database using a
centralized, web-based data entry system that contains
quality control checks (e.g., range checks, notification of
missing data). An independent Data Safety and Monitor-
ing Board, consisting a cardiologist, neurologist and a
statistician, has been set up to review mid-point results
(or at any time that a serious adverse event occurs) and
inform the investigators on issues of trial safety.
Descriptive statistics will be calculated for dependent
and independent variables. Demographic and clinical
characteristics of subjects in the experimental and con-
trol groups will be compared on admission using 2-sam-
ple t-tests (continuous data) and Chi-square analysis
(nominal data). Nonparametric methods will be used
when assumptions of normality are violated. Similar ana-
lyses will be used to compare characteristics of (i)
patients who consent to participate versus those who do
not; (ii) subjects who complete the study versus those
who withdraw, in order to determine the representative-
ness of the sample. A mixed effects analysis of variance
with repeated measures will be used to model the treat-
ment effects for variables that are interval or ratio and
conform to the assumptions of normality (i.e., BP, waist
g i r t h ,t o t a lc h o l e s t e r o l ,H D L - C ,L D L - C ,t r i g l y c e r i d e s ,
serum glucose, hemoglobin A1c, peak VO2, Six-Minute
Walk Test, step counts). Non-parametric tests (Mann
Whitney and Kruskall Wallis tests) will be used for ordi-
nal level data (i.e., International Physical Activity Ques-
tionnaire, Fatigue Assessment Scale, Montreal Cognitive
Assessment, Hospital Anxiety and Depression Scale,
Pittsburg Sleep Quality Index, Goal Attainment Scaling)
or where a normal data distribution is not found. To con-
trol for baseline differences between groups, variables
that are significantly different at baseline will serve as
covariates in the analyses. Data will be analyzed on an
intention-to-treat basis. Significant omnibus effects will
be probed with t-tests, using the Bonferroni correction to
control for multiple comparisons. Multiple regression
will be conducted where appropriate to examine relation-
ships among variables. Software will include Access and
SAS version 9.1. Alpha level will be < 0.05.
Discussion
The main focus of PREVENT Trial is to investigate the
role of aerobic exercise, education and lifestyle counsel-
ling in reducing vascular risk factors of people after TIA
or NDS. This trial will contribute much needed evidence
to begin answering important clinical questions regarding
the role of non-pharmacological interventions, modelled
after cardiac rehabilitation programs, in preventing sec-
ond stroke in the often under-served patient populations
involved in this trial. Although the trial is not sufficiently
powered to determine the effectiveness of PREVENT on
hard clinical outcomes such as second vascular events or
death, we will compare occurrence rates between groups
in order to inform future, larger scale trials.
This multi-site RCT will also explore the impact of
the PREVENT program on cardiovascular fitness, walk-
ing tolerance, fatigue, cognition, mental health, quality
of sleep, medication adherence, tobacco use, and health-
related quality of life, which may be mitigating factors in
reducing vascular risk factors, and, ultimately, stroke
recurrence. As well, comparison of the direct health
costs of the PREVENT and USUAL CARE groups over
the course of the study will provide important prelimin-
ary information related to cost effectiveness and sustain-
ability of multi-modal, behavioral interventions such as
PREVENT.
Current study status
Enrolling Patients
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